AAPL 172.69 -2.1863% MSFT 413.64 -1.9578% GOOG 156.33 -1.7966% GOOGL 154.86 -1.8196% AMZN 183.0 -1.6816% NVDA 860.01 -2.4777% META 500.23 -2.2797% TSLA 161.48 -5.5949% TSM 140.14 -1.6699% LLY 750.77 -0.1157% V 271.28 -1.6959% AVGO 1310.69 -2.4835% JPM 182.89 0.0547% UNH 445.63 1.464% NVO 123.9 -0.4899% WMT 59.93 -0.3492% LVMUY 167.15 1.0519% XOM 119.65 -0.5982% LVMHF 841.75 1.379% MA 459.79 -1.2012%
Last update at 2024-04-15T20:00:00Z
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
| Income before tax | -5.45776M | -1.74987M | -0.67292M | -0.73946M |
| Minority interest | 0.00027M | 0.04M | 0.02M | 0.03M |
| Net income | -5.16703M | -1.70883M | -0.67963M | -0.80113M |
| Selling general administrative | 5.31M | 1.29M | 0.46M | 0.60M |
| Selling and marketing expenses | 0.03M | 0.01M | 0.06M | 0.00769M |
| Gross profit | -0.00136M | 0.00000M | -0.00943M | 0.05M |
| Reconciled depreciation | - | - | - | - |
| Ebit | -5.73276M | -1.73368M | -0.64454M | -0.65124M |
| Ebitda | -5.44229M | -1.73443M | -0.64427M | -0.64877M |
| Depreciation and amortization | 0.29M | -0.00075M | 0.00027M | 0.00247M |
| Non operating income net other | - | - | - | - |
| Operating income | -5.73276M | -1.73368M | -0.64454M | -0.65124M |
| Other operating expenses | 5.74M | 1.73M | 0.77M | 0.75M |
| Interest expense | 0.02M | 0.02M | 0.03M | 0.09M |
| Tax provision | - | 0.00000M | 0.00000M | 0.00000M |
| Interest income | - | - | - | - |
| Net interest income | -0.01547M | -0.01544M | -0.02864M | -0.09069M |
| Extraordinary items | - | - | - | - |
| Non recurring | - | - | - | - |
| Other items | - | - | - | - |
| Income tax expense | -0.29074M | -0.04104M | 0.00671M | 0.06M |
| Total revenue | 0.00856M | 0.00000M | 0.12M | 0.10M |
| Total operating expenses | 5.73M | 1.73M | 0.64M | 0.70M |
| Cost of revenue | 0.00993M | 0.00000M | 0.13M | 0.05M |
| Total other income expense net | 0.27M | -0.01619M | -0.02838M | -0.08822M |
| Discontinued operations | - | - | - | - |
| Net income from continuing ops | -5.45776M | -1.74987M | -0.67292M | -0.73946M |
| Net income applicable to common shares | -5.45749M | -1.70883M | -0.65098M | -0.71044M |
| Preferred stock and other adjustments | - | - | - | - |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
| Total assets | 9.81M | 0.05M | 0.04M | 0.02M |
| Intangible assets | 0.18M | - | - | - |
| Earning assets | - | - | - | - |
| Other current assets | - | 0.00600M | - | - |
| Total liab | 0.91M | 1.25M | 0.87M | 1.24M |
| Total stockholder equity | 9.13M | -0.97458M | -0.65068M | -1.05610M |
| Deferred long term liab | - | - | - | - |
| Other current liab | 0.56M | 0.40M | 0.65M | 1.02M |
| Common stock | 0.00156M | 0.00100M | 0.00026M | 0.00010M |
| Capital stock | 0.00156M | 0.00100M | 0.00026M | 0.00010M |
| Retained earnings | -11.79446M | -6.33697M | -4.62814M | -3.97716M |
| Other liab | - | - | - | - |
| Good will | - | - | - | - |
| Other assets | - | - | - | - |
| Cash | 9.35M | 0.02M | 0.02M | 0.02M |
| Cash and equivalents | - | - | - | - |
| Total current liabilities | 0.91M | 1.25M | 0.87M | 1.24M |
| Current deferred revenue | 0.04M | - | - | - |
| Net debt | -9.20629M | -0.02176M | -0.01762M | -0.02261M |
| Short term debt | 0.15M | - | - | - |
| Short long term debt | 0.15M | - | - | - |
| Short long term debt total | 0.15M | - | - | - |
| Other stockholder equity | 20.92M | 5.36M | -0.05450M | 2.92M |
| Property plant equipment | - | - | - | - |
| Total current assets | 9.63M | 0.05M | 0.04M | 0.02M |
| Long term investments | - | - | - | - |
| Net tangible assets | 8.95M | -0.97458M | -0.65068M | -1.05610M |
| Short term investments | - | - | - | - |
| Net receivables | - | 0.00000M | 0.00093M | 0.00000M |
| Long term debt | - | - | - | - |
| Inventory | 0.02M | 0.02M | 0.02M | 0.00000M |
| Accounts payable | 0.16M | 0.85M | 0.22M | 0.21M |
| Total permanent equity | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - |
| Accumulated other comprehensive income | 20.92M | 5.36M | 4.03M | 2.92M |
| Additional paid in capital | - | - | - | - |
| Common stock total equity | - | - | - | - |
| Preferred stock total equity | - | - | - | - |
| Retained earnings total equity | - | - | - | - |
| Treasury stock | - | - | - | - |
| Accumulated amortization | - | - | - | - |
| Non currrent assets other | - | - | - | - |
| Deferred long term asset charges | - | - | - | - |
| Non current assets total | 0.18M | 0.00000M | 0.00000M | 0.00000M |
| Capital lease obligations | - | - | - | - |
| Long term debt total | - | - | - | - |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
| Investments | -0.17840M | - | - | - |
| Change to liabilities | 0.07M | 0.64M | 0.08M | -0.09682M |
| Total cashflows from investing activities | -0.17840M | -0.17840M | -0.17840M | -0.17840M |
| Net borrowings | 0.03M | 0.19M | 0.18M | 0.70M |
| Total cash from financing activities | 13.69M | 0.81M | 0.59M | 0.70M |
| Change to operating activities | -0.27548M | 0.00218M | 0.00218M | 0.00218M |
| Net income | -5.45776M | -1.74987M | -0.67292M | -0.73946M |
| Change in cash | 9.33M | 0.00413M | -0.00499M | -0.03997M |
| Begin period cash flow | 0.02M | 0.02M | 0.02M | 0.06M |
| End period cash flow | 9.35M | 0.02M | 0.02M | 0.02M |
| Total cash from operating activities | -4.17977M | -0.80907M | -0.59019M | -0.74461M |
| Issuance of capital stock | 13.65M | - | - | - |
| Depreciation | - | - | - | - |
| Other cashflows from investing activities | - | - | - | - |
| Dividends paid | - | - | - | - |
| Change to inventory | 0.02M | 0.00012M | -0.02107M | -0.02107M |
| Change to account receivables | 0.00000M | 0.00093M | -0.00093M | -0.00093M |
| Sale purchase of stock | - | - | - | - |
| Other cashflows from financing activities | 0.38M | 0.81M | 0.59M | 0.70M |
| Change to netincome | 1.46M | 0.26M | 0.00119M | 0.06M |
| Capital expenditures | 0.18M | 0.00000M | 0.00000M | 0.00000M |
| Change receivables | - | - | - | - |
| Cash flows other operating | - | - | - | - |
| Exchange rate changes | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - |
| Change in working capital | -0.18233M | 0.64M | 0.06M | -0.09682M |
| Stock based compensation | 1.73M | 0.29M | - | - |
| Other non cash items | -0.27427M | 0.00605M | 0.02M | 0.09M |
| Free cash flow | -4.35817M | -0.80907M | -0.59019M | -0.74461M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| VRAX Virax Biolabs Group Limited Ordinary Shares |
-0.065 8.78% | 0.68 | - | - | 347.01 | 0.33 | 1133.86 | 1.15 |
| NVO Novo Nordisk A/S |
-0.61 0.49% | 123.90 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
0.06 0.05% | 124.02 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
0.81 0.20% | 397.36 | 30.40 | 24.75 | 10.68 | 6.25 | 9.52 | 20.36 |
| CSLLY CSL Ltd |
-2.01 2.20% | 89.50 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
30 Broadwick Street, London, United Kingdom, W1F 8LX
| Name | Title | Year Born |
|---|---|---|
| Mr. James Foster | Chairman & CEO | 1987 |
| Mr. Jason D. Davis | Chief Financial Officer | 1972 |
| Mr. Cameron Lee Shaw | COO & Director | 1987 |
| Mr. Mark James Ternouth | Chief Technical Officer | 1968 |
| Dr. Tomasz Evan George | Chief Scientific Officer | 1984 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...